Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81


Phosphoproteome profiling reveals critical role of JAK-STAT signaling in maintaining chemoresistance in breast cancer.

Nascimento AS, Peres LL, Fari AVS, Milani R, Silva RA, da Costa Fernandes CJ, Peppelenbosch MP, Ferreira-Halder CV, Zambuzzi WF.

Oncotarget. 2017 Oct 10;8(70):114756-114768. doi: 10.18632/oncotarget.21801. eCollection 2017 Dec 29.


miRNA expression patterns in chemoresistant breast cancer tissues.

Lv J, Xia K, Xu P, Sun E, Ma J, Gao S, Zhou Q, Zhang M, Wang F, Chen F, Zhou P, Fu Z, Xie H.

Biomed Pharmacother. 2014 Oct;68(8):935-42. doi: 10.1016/j.biopha.2014.09.011. Epub 2014 Oct 5.


Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.

Wang C, Jin H, Wang N, Fan S, Wang Y, Zhang Y, Wei L, Tao X, Gu D, Zhao F, Fang J, Yao M, Qin W.

Theranostics. 2016 May 24;6(8):1205-19. doi: 10.7150/thno.15083. eCollection 2016.


Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.

Aksamitiene E, Achanta S, Kolch W, Kholodenko BN, Hoek JB, Kiyatkin A.

Cell Signal. 2011 Nov;23(11):1794-805. doi: 10.1016/j.cellsig.2011.06.014. Epub 2011 Jun 25.


A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.

Kim BH, Yin CH, Guo Q, Bach EA, Lee H, Sandoval C, Jayabose S, Ulaczyk-Lesanko A, Hall DG, Baeg GH.

Mol Cancer Ther. 2008 Sep;7(9):2672-80. doi: 10.1158/1535-7163.MCT-08-0309.


Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Meyer SC, Levine RL.

Clin Cancer Res. 2014 Apr 15;20(8):2051-9. doi: 10.1158/1078-0432.CCR-13-0279. Epub 2014 Feb 28. Review.


Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.

Lv J, Fu Z, Shi M, Xia K, Ji C, Xu P, Lv M, Pan B, Dai L, Xie H.

Biomed Pharmacother. 2015 Feb;69:162-9. doi: 10.1016/j.biopha.2014.11.028. Epub 2014 Nov 25.


Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs.

Chuthapisith S, Layfield R, Kerr ID, Hughes C, Eremin O.

Int J Oncol. 2007 Jun;30(6):1545-51.


Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters.

Kong Y, Peng Y, Liu Y, Xin H, Zhan X, Tan W.

Stem Cells. 2015 Apr;33(4):1063-74. doi: 10.1002/stem.1955.


JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.

Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM.

Drugs. 2017 Apr;77(5):521-546. doi: 10.1007/s40265-017-0701-9. Review. Erratum in: Drugs. 2017 May;77(8):939. Drugs. 2017 Jun 12;:.


GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling.

Khanna P, Lee JS, Sereemaspun A, Lee H, Baeg GH.

Sci Rep. 2018 Jun 22;8(1):9511. doi: 10.1038/s41598-018-27864-6.


Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray.

Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME.

Surgery. 2002 Aug;132(2):293-301.


A marine anthraquinone SZ-685C overrides adriamycin-resistance in breast cancer cells through suppressing Akt signaling.

Zhu X, He Z, Wu J, Yuan J, Wen W, Hu Y, Jiang Y, Lin C, Zhang Q, Lin M, Zhang H, Yang W, Chen H, Zhong L, She Z, Chen S, Lin Y, Li M.

Mar Drugs. 2012 Apr;10(4):694-711. doi: 10.3390/md10040694. Epub 2012 Mar 23.


miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27kip1 pathway.

Wang DD, Yang SJ, Chen X, Shen HY, Luo LJ, Zhang XH, Zhong SL, Zhao JH, Tang JH.

Tumour Biol. 2016 Nov;37(11):15315-15324. Epub 2016 Oct 4.


Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway.

Uluer ET, Aydemir I, Inan S, Ozbilgin K, Vatansever HS.

Acta Histochem. 2012 Nov;114(7):641-6. doi: 10.1016/j.acthis.2011.11.010. Epub 2011 Dec 14.


Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS.

Gastroenterology. 2006 Apr;130(4):1117-28.


RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.

Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra122. doi: 10.1126/scisignal.2005301.


Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Coskun M, Salem M, Pedersen J, Nielsen OH.

Pharmacol Res. 2013 Oct;76:1-8. doi: 10.1016/j.phrs.2013.06.007. Epub 2013 Jul 2. Review.


Supplemental Content

Support Center